In children aged 10 to <18 with T2D inadequately controlled on standard of care treatment, tirzepatide reduced HbA1c by an average of 2.2% and reduced BMI as well.
Most parents support childhood vaccines such as MMR and polio, but skepticism about seasonal and newer shots persists, along with distrust of federal agencies.
Merck's CAPVAXIVE could cover approximately 78% of invasive pneumococcal disease cases in youth with chronic health conditions, vs other approved pneumococcal conjugate vaccines.